BSE: 544250 | NSE: SANOFICONR | Pharmaceuticals & Drugs |
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sanofi Consumer Healthcare India Ltd is a below average quality company.
The key valuation ratios of Sanofi Consumer Healthcare India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sanofi Consumer Healthcare India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
No data to display
Return on Equity has declined versus last 3 years average to 0.00%
Standalone | Consolidated | |
---|---|---|
TTM EPS (₹) | - | - |
TTM Sales (₹ Cr.) | - | - |
BVPS (₹.) ⓘ | - | - |
Reserves (₹ Cr.) ⓘ | - | - |
P/BV ⓘ | - | - |
PE ⓘ | - | - |
From the Market | |
---|---|
52 Week Low / High (₹) | 4360.30 / 5499.00 |
All Time Low / High (₹) | 4360.30 / 5499.00 |
Market Cap (₹ Cr.) | - |
Equity (₹ Cr.) | - |
Face Value (₹) | - |
Industry PE ⓘ | - |
Dec'23 | YoY Gr. Rt. % | Jun'24 | YoY Gr. Rt. % | Sep'24 | YoY Gr. Rt. % | Dec'24 | YoY Gr. Rt. % | |
---|---|---|---|---|---|---|---|---|
Sales (₹ Cr.)ⓘ | 225 | N/A | 164 | 63.9 | 160 | -24 | 171 | -24 |
Adj EPS (₹) ⓘ | 27.7 | N/A | 20 | 78.3 | 19.9 | -35.6 | 20.1 | -27.2 |
Op. Profit Mgn % ⓘ | 39.85 | N/A | 38.69 | 409 bps | 39.46 | -552 bps | 36.38 | -347 bps |
Net Profit Mgn % ⓘ | 30.79 | N/A | 27.99 | 227 bps | 28.67 | -519 bps | 27.14 | -365 bps |
Pledged * | 0.00 | 0.00 |
Company Name | CMP(₹) | |||||||
---|---|---|---|---|---|---|---|---|
Sun Pharma Inds. | 1,697.9 | 29.5 (1.8%) | Large Cap | 48,497 | 47.7 | 20.9 | 35 | 5.6 |
Dr. Reddys Lab | 1,108.4 | 19.8 (1.8%) | Large Cap | 28,011 | 64.4 | 19.6 | 16.9 | 2.8 |
Cipla | 1,426.1 | 41.7 (3%) | Large Cap | 25,774 | 61.8 | 15.6 | 22.4 | 3.7 |
Lupin | 1,984.7 | 61.8 (3.2%) | Mid Cap | 20,011 | 62.8 | 9.7 | 30.6 | 5.3 |
Zydus Lifesciences | 860.2 | 22.8 (2.7%) | Large Cap | 19,547 | 45.1 | 19.3 | 18.6 | 3.7 |
Glenmark Pharma | 1,438.3 | -3 (-0.2%) | Mid Cap | 11,813 | -6.2 | -10.2 | - | 4.6 |
Torrent Pharma | 3,227.9 | -4.7 (-0.2%) | Large Cap | 10,728 | 55 | 14.8 | 58.8 | 13.7 |
Aurobindo Pharma | 1,099.3 | 4.2 (0.4%) | Mid Cap | 10,646 | 33 | 17.2 | 33.2 | 3.2 |
Alkem Laboratories | 4,831.2 | 131.2 (2.8%) | Mid Cap | 9,748 | 190.9 | 18.1 | 24.6 | 4.5 |
Mankind Pharma | 2,415.1 | 36.7 (1.5%) | Mid Cap | 9,265 | 47.4 | 19.6 | 50.1 | 6.9 |